Triage DD of short bowel syndrome assets

Challenge: For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three...
Learn More

Due diligence on a bladder cancer gene therapy

Challenge: A European investment trust was considering an investment in a Phase 3 gene therapy opportunity targeting a niche oncology indication. Owing to the circumstances of the deal, they had less...
Learn More

Technical & Commercial Due Diligence of a Portfolio of Biotech Companies

Challenge: A PE fund was looking at the potential purchase of a package of minority holdings in a portfolio of biotech companies on the secondary market. The fund approached Alacrita to conduct a due...
Learn More

Technical due diligence for a high-profile M&A transaction

Challenge: For a competitive M&A transaction, Alacrita was commissioned to conduct a technical due diligence of a major public drug delivery contract development and manufacturing organization. This...
Learn More

Due diligence on a product for ARDS in COVID-19 patients

Challenge: A family office was considering an investment in a US-based biotech company developing a product aimed at improving impaired oxygen transport in COVID-19 patients. Using its expert...
Learn More

Pre-DD on portfolio of repurposed drug products targeting CNS indications

Challenge: A VC firm was interested in a US-based drug repurposing company and asked Alacrita to perform a high level technical due diligence exercise to help the firm make an informed decision about...
Learn More

Due Diligence on a bioinformatics platform to repurpose clinical-stage drugs

Challenge: Our client, a VC firm based in Dubai, was planning to invest in a US-based therapeutics company and asked Alacrita to perform a technical DD. The target company was using a proprietary...
Learn More

Due diligence on a reverse merger candidate with pipeline of IND-ready compounds

Challenge: A NASDAQ-listed biotech asked Alacrita to conduct a technical due diligence on a prospect reverse merger candidate. After screening numerous companies, our client identified a strong...
Learn More

Due diligence of first-in-class monoclonal antibody candidate drug

Challenge: A biopharma company required expert due diligence for a potential transaction with a clinical stage biotech focusing in inflammation and fibrosis. Alacrita was commissioned to provide an...
Learn More

Pre-due diligence of two early-stage assets: a nano-ADC & a small molecule

Challenge: A pharma company sought Alacrita's support in providing high-level go/no-go pre-due diligence of two early-stage strategic investment opportunities. The company had so far been focused on...
Learn More

Technical & commercial due diligence of two pipeline cell therapy products

Challenge: Alacrita was engaged due diligence and valuation support by a listed clinical stage biotechnology company. The biotech needed to benchmark the technical strengths and weaknesses of two...
Learn More

Due diligence on reinvestment in VC-backed biotech

Challenge: A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology space. The...
Learn More